PharmacoEconomics & Outcomes News

, Volume 819, Issue 1, pp 26–26 | Cite as

Nivolumab not cost effective in advanced NSCLC in Australia

Clinical study


  1. Gao L, et al. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models. Applied Health Economics and Health Policy : 10 Dec 2018. Available from: URL:

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations